Research Article
Cost-Effectiveness Analysis of Fosfomycin for Treatment of Uncomplicated Urinary Tract Infections in Ontario
Table 3
Results of tornado diagram (decision node).
| Variable | Range | Low EV | High EV | Spread | Spread2 | Risk (%) | Cumulative risk (%) | Variable index |
| Probability of developing PN | 0.0 to 0.08 | 88.93 | 103.46 | 14.530 | 211.121 | 0.553 | 0.553 | 0 | Probability of hospitalization for PN | 0.0 to 0.4 | 90.56 | 101.83 | 11.270 | 127.013 | 0.332 | 0.885 | 1 | Probability of resistance of E. coli to TMP–SMX | 0.141 to 0.294 | 92.64 | 96.96 | 4.320 | 18.662 | 0.049 | 0.934 | 2 | Cost of hospitalization for PN | 4842.71 to 8993.60 | 94.41 | 97.98 | 3.570 | 12.745 | 0.033 | 0.967 | 3 | Cost of nitrofurantoin | 4.68 to 11.12 | 93.51 | 96.20 | 2.690 | 7.236 | 0.019 | 0.986 | 4 | Probability of being infected by E. coli | 0.767 to 0.918 | 95.56 | 96.86 | 1.300 | 1.690 | 0.004 | 1 | 5 | Probability of resistance of E. coli to nitrofurantoin | 0.0016 to 0.019 | 96.20 | 96.20 | 0.000 | 0.000 | 0.000 | 1 | 6 | Probability of resistance of E. coli to fosfomycin | 0.004 to 0.012 | 96.20 | 96.20 | 0.000 | 0.000 | 0.000 | 1 | 7 | Probability of resistance of E. coli to ciprofloxacin | 0.191 to 0.245 | 96.20 | 58.69 | 0 | 0 | 0.000 | 1 | 8 | Cost of ciprofloxacin | 3.71 to 11.78 | 96.20 | 96.20 | 0.000 | 0.000 | 0.000 | 1 | 9 | Cost of fosfomycin | 13.0 to 18.0 | 96.20 | 58.69 | 0 | 0 | 0.000 | 1 | 10 |
|
|
EV, expected value; PN, pyelonephritis.
|